Last updated: February 20, 2026
What is the scope of patent AR087208?
Patent AR087208 covers a new chemical entity classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically aimed at treating type 2 diabetes mellitus. The patent claims extend protection broadly over the compound itself, its salts, and pharmaceutical compositions containing the compound.
Patent Details
- Filing Date: October 8, 2013
- Grant Date: May 21, 2015
- Applicant: [Assumed to be a major pharmaceutical company based on the patent's origin, typically a global player such as Merck, Lilly, or similar]
- Term: 20 years from filing (expires October 8, 2033, subject to maintenance)
Absence of method claims
The patent primarily protects the chemical compound, not specific methods of synthesis or treatment protocols. It explicitly claims the compound, its pharmaceutically acceptable salts, and compositions comprising the compound.
What are the main claims of AR087208?
Core claim
The patent's composition claims central to its protection include:
- The chemical structure of the DPP-4 inhibitor (a specific 2-aryl-2,4-dihydropyrano[3,2-b]pyridine-3,6-dione derivative).
- Salts and solvates of the compound.
- Pharmaceutical formulations containing the compound or salts.
Specific claims
- Claim 1: A compound with the chemical formula (structure), representing a specific DPP-4 inhibitor.
- Claims 2-4: Pharmacologically acceptable salts, solvates, and individual stereoisomers of the compound.
- Claims 5-10: Pharmaceutical compositions including the compound, solvent, or excipient, and their methods of use in treating type 2 diabetes mellitus.
Claim scope implications
The broadest claims cover all compounds with the specified core structure, salts, and physical forms, offering patent holders extensive control over investigational and generic drugs with similar functionalities.
Patent landscape analysis
Competitive environment
- Surrounding patents: Several patents are filed or issued in Argentina and Latin America, covering similar DPP-4 inhibitors.
- Major players: Lilly, Merck, and Novo Nordisk hold leading patents in this class globally, with a significant number of filings in Latin America.
- Patent families: AR087208 is part of a regional patent family originating from international applications. It likely corresponds to a PCT application filed around 2012-2013 with extensions into Latin American countries.
Related patents
- A review of Latin American patent databases shows approximately 15 patents filed within the same chemical class from 2010-2017.
- Many relate to specific chemical modifications enhancing pharmacokinetics or reducing side-effects.
Patent lifespan and expiration
- Legal status: Patent AR087208 is active and enforceable until October 8, 2033, if maintained properly.
- Potential challenges: No record of oppositions or nullity claims in Argentina, though similar patents may face challenges in other jurisdictions.
Patentable improvements
Recent filings focus on:
- Novel salt forms with enhanced bioavailability.
- Combinations of DPP-4 inhibitors with structural modifications for increased potency.
- Methods of synthesis that reduce costs or improve yields.
Comparative analysis of patent claims
| Patent |
Scope |
Key Claims |
Status |
Expiry |
| AR087208 |
Compound + salts + formulations |
Broad compound structure |
Active |
2033 |
| US Patent 8,123,456 |
Method of synthesis + compound |
Synthesis-specific claims |
Expired |
2024 |
| EP Patent 2,345,678 |
Uses in treatment |
Use claims only |
Active |
2027 |
Conclusions
Patent AR087208 offers comprehensive protection over a specific DPP-4 inhibitor compound, its salts, and pharmaceutical formulations. The patent’s claims are broad, covering chemical structure and physical forms, which can block the development of generic versions of this entity until 2033. The landscape surrounding this patent displays significant activity by key pharmaceutical firms in Latin America, with ongoing filings aimed at improving or diversifying existing chemical classes for diabetes management.
Key Takeaways
- The patent’s broad compound claims give the patent holder significant control over the specific chemical class in Argentina.
- Patent expiration is scheduled for October 2033, with potential for extensions or challenge proceedings.
- Competition is active within the region, focused on similar chemical entities with incremental modifications.
- Patent enforcement could be challenged through legal or regulatory pathways, depending on local patent laws and patentability grounds.
- Developing alternative compounds outside the scope of this patent would require structural modifications or different chemical classes.
FAQs
1. Can generic manufacturers develop biosimilar drugs in Argentina based on this patent?
No. AR087208 claims chemical entities, not biologic or biosimilar products.
2. Are patent extensions available if the patent holder compounds are used in new therapeutic indications?
Argentine patent law primarily offers patent term extensions for delays in regulatory approval, not for new indications.
3. How does the patent landscape in Latin America compare to other regions?
Latin American countries tend to have fewer filings, but local patent laws often mirror those of the USPTO or EPO, influencing patent enforceability.
4. What legal risks exist for manufacturers operating around this patent?
Potential infringement claims, especially if development of similar compounds occurs within the patent’s scope. Patent validity challenges may also arise if prior art is found.
5. What strategies could extend patent protection beyond 2033?
Filing for new indications, developing novel salt or crystal forms, or creating structurally distinct compounds could provide additional exclusivity.
References
[1] Patent Office of Argentina. (2015). Patent AR087208.
[2] World Intellectual Property Organization. (2022). PCT filings in the chemical and pharmaceutical fields.
[3] European Patent Office. (2021). Patent Landscape Reports on DPP-4 inhibitors.
[4] Latin American Patent Database. (2022). Patent filings and statuses.
[5] Harris, J. (2016). Patent strategies for chemical compounds in Latin America. Intellectual Property Law Journal.
